Generic Name and Formulations:
Quinupristin/dalfopristin 500mg per vial (as 150mg quinupristin and 350mg dalfopristin); pwd for IV infusion after reconstitution; preservative-free.
Indications for SYNERCID:
Treatment of complicated skin and skin structure infections due to S. aureus (methicillin-susceptible) or S. pyogenes.
Give by IV infusion over 60mins. ≥16yrs: 7.5mg/kg every 12hrs for at least 7 days.
<16yrs: not established; doses of 7.5 mg/kg every 8hrs or 12hrs have been used in a limited number of children under emergency-use conditions (see full labeling).
Hepatic insufficiency. Pregnancy. Nursing mothers.
Avoid concomitant drugs known to prolong the QT interval. Potentiates CYP3A4 substrates (eg, midazolam, nifedipine, cisapride, carbamazepine, vinca alkaloids, taxanes, steroids, NNRTIs, protease inhibitors, statins); monitor esp. those with narrow therapeutic window (eg, cyclosporine, tacrolimus). May affect digoxin.
Inj site reactions, arthralgia, myalgia, GI upset, thrombophlebitis, rash, headache, pruritus; C. difficile-associated diarrhea.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC